Tag:
NI-0501
Latest Headlines
Latest Headlines
NovImmune raises $54.8M to buy back drug rights
Switzerland's NovImmune has rounded up $54.8 million (CHF 62.5 million) to take back control of its lead compounds NI-0401 and NI-0501 from MerckSerono. The company said the money will also be used
